Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market, Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Pfizer, Spark Therapeutics, REGENXBIO

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline constitutes key companies continuously working towards developing Neuronal Ceroid-Lipofuscinoses (CLN1 disease) treatment therapies, analyzes DelveInsight.

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Overview:

Neuronal Ceroid-Lipofuscinoses (NCLs), including CLN1 disease, are a group of rare, inherited neurodegenerative disorders. CLN1 disease, also known as Infantile NCL (INCL) or Batten disease (CLN1 subtype), is caused by mutations in the PPT1 (palmitoyl-protein thioesterase 1) gene. This leads to the accumulation of lipopigments (lipofuscin) in neurons and other cells, resulting in progressive neurological decline.

Request for a detailed insights report on Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline insights @ https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

DelveInsight's "Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Neuronal Ceroid-Lipofuscinoses (CLN1 disease), historical and forecasted epidemiology as well as the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Takeaways from the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Report

DelveInsight's Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline report depicts a robust space with active players working to develop pipeline therapies for Neuronal Ceroid-Lipofuscinoses (CLN1 disease) treatment.
Key Neuronal Ceroid-Lipofuscinoses (CLN1 disease) companies such as Pfizer, Spark Therapeutics, REGENXBIO, and others are evaluating new drugs for Neuronal Ceroid-Lipofuscinoses (CLN1 disease) to improve the treatment landscape.

Recent breakthroughs in the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Segment:

In May 2019, Abeona Therapeutics received FDA clearance for their IND application to initiate a Phase 1/2 clinical trial of ABO-202, an AAV9-based gene therapy designed to deliver a functional copy of the PPT1 gene to the central nervous system and peripheral organs.
In June 2019, the FDA granted Fast Track designation to ABO-202, recognizing its potential to address the unmet medical needs of patients with CLN1 disease.

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuronal Ceroid-Lipofuscinoses (CLN1 disease) treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) market.

Download our free sample page report on Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline insights @ https://www.delveinsight.com/sample-request/neuronal-ceroid-lipofuscinoses-cln1-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Companies

Around three or more key companies such as Pfizer, Spark Therapeutics, REGENXBIO, and others are actively developing therapies for Neuronal Ceroid-Lipofuscinoses (CLN1 disease) (CRPS).

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Therapies and Key Companies: Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Clinical Trials and advancements @ https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Therapeutic Assessment
• Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Assessment by Product Type
• Neuronal Ceroid-Lipofuscinoses (CLN1 disease) By Stage
• Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Assessment by Route of Administration
• Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Assessment by Molecule Type

Download Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Sample report to know in detail about the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) treatment market @ Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Therapeutic Assessment @ https://www.delveinsight.com/sample-request/neuronal-ceroid-lipofuscinoses-cln1-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Current Treatment Patterns
4. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Late-Stage Products (Phase-III)
7. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Discontinued Products
13. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Product Profiles
14. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Key Companies
15. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Key Products
16. Dormant and Discontinued Products
17. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Unmet Needs
18. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Future Perspectives
19. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Reports Offerings: https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.